This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and doublet chemotherapy for first line treatment of non-squamous non-small cell lung cancer (NSCLC).

The strength of the early clinical data in this first-in-man triple combination study led to its increase to 50 patients. The extension opened in mid-2023 and 29 patients have been enrolled to date. With the addition of the new sites, the trial is expected to complete recruitment in 1H CY2024.

As presented at ESMO Congress 2023, the triple combination in INSIGHT-003 achieved a 70.6% overall response rate and 10.9-month median progression-free survival¹ in patients with PD-L1 Tumor Proportion Score (TPS) of <50%, who are typically less responsive to anti-PD-1 therapy. This compares favourably to data in the same patient population, including a response rate of 40.8%, from a registrational trial of anti-PD-1 and doublet chemotherapy.²

Furthermore, the triple combination is well tolerated, and the addition of efti does not appear to increase the toxicity of KEYTRUDA® and carboplatin/pemetrexed, building upon the favourable safety profile of efti that has been established across multiple clinical trials to date.